Randomized phase III study of 5-FU [fluorouracil] continuous infusion (5-FUci) versus CPT-11 [irinotecan] plus CDDP (CP) [cisplatin] versus S-1 alone (S-1) in advanced gastric cancer (JCOG9912).
Phase of Trial: Phase III
Latest Information Update: 14 Sep 2016
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary) ; Cisplatin; Fluorouracil
- Indications Gastric cancer
- Focus Registrational; Therapeutic Use
- 15 Dec 2009 Actual end date (Jan 2007) added as reported by ClinicalTrials.gov.
- 15 Dec 2009 Additional lead trial centres identified as reported by ClinicalTrials.gov.
- 15 Dec 2009 Taiho Pharmaceutical Co., Ltd. and Yakult Honsha Co., LTD added as trial sponsors as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History